Resources

Type of publications
Regions
Diseases

5255 results found

2018 ∙ Jefferson, T. Rivetti, A. Di Pietrantonj, C. Demicheli, V.

Vaccines for preventing influenza in healthy children

  • Newborn
  • Children
  • Adolescents
  • Influenza
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2018 ∙ Demicheli, V. Jefferson, T. Di Pietrantonj, C. Ferroni, E. Thorning, S. Thomas, R. E. Rivetti, A.

Vaccines for preventing influenza in the elderly

  • Older adults
  • Influenza
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2018 ∙ Odey, F. Okomo, U. Oyo‐Ita, A.

Vaccines for preventing invasive salmonella infections in people with sickle cell disease

  • All age groups
  • Salmonella
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2018 ∙ Milligan, R. Paul, M. Richardson, M. Neuberger, A.

Vaccines for preventing typhoid fever

  • Children
  • Adolescents
  • Adults
  • Typhoid
  • Safety
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
High
2018 ∙ SAGE

Meeting of the Strategic Advisory Group of Experts on Immunization, October 2018 – Conclusions and recommendations

  • Meeting report
  • Measles
  • Poliomyelitis
Download:
2018 ∙ SAGE

What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?

  • GRADE table
  • Dengue
Download:
2018 ∙ SAGE

What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?

  • GRADE table
  • Dengue
Download:
2018 ∙ SAGE

Should countries considering introduction of CYD-TDV to reduce the burden of dengue use a pre-vaccination screening or population seroprevalence based criteria?

  • Evidence to recommendation table
  • Dengue
Download:
2018 ∙ SAGE

Should CYD-TDV be recommended, over no vaccination, to immunocompetent individuals (≥9 years of age) in dengueendemic countries to mitigate the dengue burden of disease?

  • Evidence to recommendation table
  • Dengue
Download:
2018 ∙ SAGE

What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?

  • GRADE table
  • Dengue
Download:
Loading...